Neurocrine Biosciences pipeline update: what analysts should watch next
Decision brief
Answer first · skim in under a minute
Neurocrine Biosciences pipeline remains centered on neurology, endocrinology, psychiatry, and immunology, with an early-stage update flagged for 2026. For analysts and BD teams, the main watchpoints are elagolix-related clinical activity, filing cadence, and the next disclosed catalyst in early-stage neurology and immunology.
Neurocrine Biosciences pipeline watchlists should start with CRENESSITY (crinecerfont), the FDA-approved CRF1 antagonist for classic congenital adrenal hyperplasia, then layer mid-stage neurology and psychiatry assets only when NCT IDs and labels are current.
Contents11 sections
Key Takeaways
- FDA approved Crenessity on 13 December 2024 as adjunctive treatment with glucocorticoids to control androgens in classic CAH patients ≥4 years (PR Newswire FDA release).
- Adult Phase 3: glucocorticoid daily dose fell 27% with Crenessity vs 10% with placebo while maintaining androstenedione control (182 adults; 122 vs 60).
- Pediatric Phase 3: 103 children; Crenessity cut androstenedione at week 4 vs placebo rise; glucocorticoid dose −18% vs +6% near placebo at end.
- NCT07536269 is a Phase 2 open-label study of crinecerfont in classic CAH ages 3 months to <4 years (not yet recruiting as listed).
What did FDA approve for CRENESSITY?
The FDA PR Newswire announcement dated 13 December 2024 approved Crenessity (crinecerfont) with glucocorticoids to control androgen levels in adults and pediatric patients 4 years and older with classic CAH.
Which Phase 3 numbers are on the public record?
Adult trial (24 weeks): 122 patients on Crenessity vs 60 on placebo; glucocorticoid dose −27% vs −10% while keeping androstenedione control. Pediatric trial (28 weeks): 69 vs 34; primary endpoint was week-4 androstenedione change, favoring Crenessity; end-of-trial glucocorticoid change −18% vs about +6% on placebo.
What pediatric expansion study is listed next?
NCT07536269 is a Phase 2 open-label Neurocrine study of safety, tolerability, PK and PD of crinecerfont in classic CAH participants 3 months to under 4 years. Listed status was not yet recruiting, with estimated start April 2026 and primary completion March 2028.
How should analysts read the broader Neurocrine stack?
Ingrezza and other marketed neurology products still fund R&D. Separate CAH launch metrics from VMAT2 franchise cash when sizing CRENESSITY peak share. Prefer FDA Drugs@FDA labels over secondary launch blogs.
What safety warnings matter in diligence?
FDA’s release warns about acute adrenal insufficiency/crisis if glucocorticoid replacement is inadequate during stress. Drug-interaction language covers enzyme inducers that can lower exposure.
What remains unproven after approval?
Real-world steroid-sparing durability beyond trial windows, adherence in adolescents, and outcomes under age 4 (NCT07536269 still early) are open. Avoid inventing U.S. peak-sales dollars.
What 2025–2026 commercial questions follow the CAH approval?
Neurocrine Biosciences pipeline models should track CRENESSITY new-patient starts after the 13 December 2024 approval, steroid-dose trajectories matching the −27% vs −10% adult and −18% vs +6% pediatric trial contrasts, and whether NCT07536269 (target n=20, start April 2026) expands the under-4 label later.
Separate Ingrezza franchise cash from CAH launch metrics in 2025–2026 quarterly reads. If adherence or adrenal-crisis warnings slow titration, 27% mean steroid reduction may not replicate outside CAHtalyst sites.
Related NovaPharma coverage
- Neurocrine Crenessity two-year pediatric CAH study
- Neurocrine NBIP-2118 Phase 1
- Syndax pipeline update
Frequently Asked Questions
What is CRENESSITY (crinecerfont)?
It is an oral CRF1 receptor antagonist FDA-approved on 13 December 2024 as adjunctive therapy with glucocorticoids to control androgens in classic CAH patients 4 years of age and older.
What efficacy did the adult Phase 3 show?
In 182 adults, patients on Crenessity reduced daily glucocorticoid dose by 27% versus 10% on placebo while maintaining androstenedione control after dose titration.
What is NCT07536269?
A Phase 2 open-label Neurocrine study evaluating crinecerfont safety and pharmacology in classic CAH patients from 3 months to under 4 years of age.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for elagolix.
Unlock full calendar →NEUROCRINE BIOSCIENCES INC pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
